261 related articles for article (PubMed ID: 28624063)
1. Acceptance of adjuvant chemotherapy recommendations in early-stage hormone-positive breast cancer.
Marcinkowski EF; Ottesen R; Niland J; Vito C
J Surg Res; 2017 Jun; 214():79-85. PubMed ID: 28624063
[TBL] [Abstract][Full Text] [Related]
2. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
3. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results.
Press DJ; Ibraheem A; Dolan ME; Goss KH; Conzen S; Huo D
Breast Cancer Res Treat; 2018 Feb; 168(1):207-220. PubMed ID: 29181717
[TBL] [Abstract][Full Text] [Related]
4. Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015.
Reyes SA; De La Cruz LM; Ru M; Pisapati KV; Port E
Ann Surg Oncol; 2019 Oct; 26(10):3397-3408. PubMed ID: 31429016
[TBL] [Abstract][Full Text] [Related]
5. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists.
Hurria A; Wong FL; Pal S; Chung CT; Bhatia S; Mortimer J; Somlo G; Hurvitz S; Villaluna D; Naeim A
Oncologist; 2009 Sep; 14(9):883-90. PubMed ID: 19726455
[TBL] [Abstract][Full Text] [Related]
6. Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center.
Fayaz S; Eissa HE; Demian GA
J Egypt Natl Canc Inst; 2020 Mar; 32(1):13. PubMed ID: 32372329
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States.
Mohiuddin JJ; Deal AM; Carey LA; Lund JL; Baker BR; Zagar TM; Jones EL; Marks LB; Chen RC
J Am Coll Surg; 2016 Nov; 223(5):717-728.e4. PubMed ID: 27788894
[TBL] [Abstract][Full Text] [Related]
8. Is Age Trumping Genetic Profiling in Clinical Practice? Relationship of Chemotherapy Recommendation and Oncotype DX Recurrence Score in Patients Aged < 50 Years versus ≥ 50 Years, and Trends Over Time.
Williams AD; Reyes SA; Arlow RL; Tchou J; De La Cruz LM
Ann Surg Oncol; 2018 Oct; 25(10):2875-2883. PubMed ID: 29959613
[TBL] [Abstract][Full Text] [Related]
9. The Impact of the Oncotype DX Breast Cancer Assay on Treatment Decisions for Women With Estrogen Receptor-Positive, Node-Negative Breast Carcinoma in Hong Kong.
Leung RC; Yau TC; Chan MC; Chan SW; Chan TW; Tsang YY; Wong TT; Chao C; Yoshizawa C; Soong IS; Kwan WH; Kwok CC; Suen JS; Ngan RK; Cheung PS
Clin Breast Cancer; 2016 Oct; 16(5):372-378. PubMed ID: 27105769
[TBL] [Abstract][Full Text] [Related]
10. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
11. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer.
Silliman RA; Guadagnoli E; Rakowski W; Landrum MB; Lash TL; Wolf R; Fink A; Ganz PA; Gurwitz J; Borbas C; Mor V
J Clin Oncol; 2002 Jun; 20(11):2680-8. PubMed ID: 12039930
[TBL] [Abstract][Full Text] [Related]
13. Impact of CALGB 9343 Trial and Sociodemographic Variation on Patterns of Adjuvant Radiation Therapy Practice for Elderly Women (≥70 Years) with Stage I, Estrogen Receptor-positive Breast Cancer: Analysis of the National Cancer Data Base.
Chu QD; Zhou M; Medeiros KL; Peddi P; Wu XC
Anticancer Res; 2017 Oct; 37(10):5585-5594. PubMed ID: 28982874
[TBL] [Abstract][Full Text] [Related]
14. Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?
Ibraheem AF; Press DJ; Olopade OI; Huo D
Cancer; 2019 Jan; 125(2):213-222. PubMed ID: 30387876
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant chemotherapy and differential invasive breast cancer specific survival in elderly women.
Kaplan HG; Malmgren JA; Atwood MK
J Geriatr Oncol; 2013 Apr; 4(2):148-56. PubMed ID: 24071540
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
17. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
DeMichele A; Putt M; Zhang Y; Glick JH; Norman S
Cancer; 2003 May; 97(9):2150-9. PubMed ID: 12712466
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
Zhu X; Dent S; Paquet L; Zhang T; Graham N; Song X
Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
[TBL] [Abstract][Full Text] [Related]
19. Oncotype DX
Rath MG; Uhlmann L; Fiedler M; Heil J; Golatta M; Dinkic C; Hennigs A; Schott S; Ernst V; Koch T; Sohn C; Brucker C; Rom J
Arch Gynecol Obstet; 2018 Feb; 297(2):443-447. PubMed ID: 29236174
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy decisions in clinical practice for early-stage node-negative, estrogen receptor-positive, HER2-negative breast cancer: challenges and considerations.
Nagaraj G; Ma CX
J Natl Compr Canc Netw; 2013 Mar; 11(3):246-50; quiz 251. PubMed ID: 23486451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]